These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16887480)

  • 1. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
    ; Buzdar A; Howell A; Cuzick J; Wale C; Distler W; Hoctin-Boes G; Houghton J; Locker GY; Nabholtz JM
    Lancet Oncol; 2006 Aug; 7(8):633-43. PubMed ID: 16887480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial.
    Haddad TC; Suman VJ; Giridhar KV; Sideras K; Northfelt DW; Ernst BJ; O'Sullivan CC; Singh RJ; Desta Z; Peethambaram PP; Hobday TJ; Chumsri S; Leon-Ferre RA; Ruddy KJ; Yadav S; Taraba JL; Goodnature B; Goetz MP; Wang L; Ingle JN
    Clin Cancer Res; 2024 Aug; 30(15):3147-3156. PubMed ID: 38752717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of change in cognitive function with anastrozole therapy.
    Bender CM; Merriman JD; Gentry AL; Ahrendt GM; Berga SL; Brufsky AM; Casillo FE; Dailey MM; Erickson KI; Kratofil FM; McAuliffe PF; Rosenzweig MQ; Ryan CM; Sereika SM
    Cancer; 2015 Aug; 121(15):2627-36. PubMed ID: 25906766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
    van Hellemond IEG; Smorenburg CH; Peer PGM; Swinkels ACP; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Tjan-Heijnen VCG;
    Int J Cancer; 2019 Sep; 145(5):1325-1333. PubMed ID: 30748011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
    Van Poznak C; Makris A; Clack G; Barlow DH; Eastell R
    Breast Cancer Res Treat; 2012 Aug; 134(3):1141-7. PubMed ID: 22763465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial.
    Hale MJ; Howell A; Dowsett M; Cuzick J; Sestak I
    Breast; 2020 Dec; 54():216-221. PubMed ID: 33160147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
    Garber JE; Halabi S; Tolaney SM; Kaplan E; Archer L; Atkins JN; Edge S; Shapiro CL; Dressler L; Paskett ED; Kimmick G; Orcutt J; Scalzo A; Winer E; Levine E; Shahab N; Berliner N;
    J Natl Cancer Inst; 2010 Jul; 102(13):942-9. PubMed ID: 20554945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer.
    Aydiner A; Tas F
    Trials; 2008 Jul; 9():47. PubMed ID: 18664277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
    Buijs SM; Koolen SLW; Mathijssen RHJ; Jager A
    Drugs; 2024 Apr; 84(4):385-401. PubMed ID: 38480629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer.
    Koleck TA; Bender CM; Sereika SM; Ryan CM; Ghotkar P; Brufsky AM; Jankowitz RC; McAuliffe PF; Clark BZ; Conley YP
    Cancer Med; 2017 Feb; 6(2):339-348. PubMed ID: 28083945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of arthralgias associated with aromatase inhibitor therapy.
    Thorne C
    Curr Oncol; 2007 Dec; 14 Suppl 1(Suppl 1):S11-9. PubMed ID: 18087604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data.
    Luu M; Gresham G; Henry L; Kim S; Rogatko A; Yothers G; Hays RD; Tighiouart M; Ganz PA
    JCO Clin Cancer Inform; 2024 Jul; 8():e2400007. PubMed ID: 39013121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Authorization of anastrazole to prevent breast cancer in postmenopausal women: a bad idea.
    Glynne SJ; Bluming AZ
    Climacteric; 2024 Apr; 27(2):215-216. PubMed ID: 38265057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
    ; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
    Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
    Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
    Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
    ; Davies C; Godwin J; Gray R; Clarke M; Cutter D; Darby S; McGale P; Pan HC; Taylor C; Wang YC; Dowsett M; Ingle J; Peto R
    Lancet; 2011 Aug; 378(9793):771-84. PubMed ID: 21802721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
    Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
    Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Knauer M; Moik M; Jakesz R; Seifert M; Taucher S; Bjelic-Radisic V; Balic M; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Selim U; Fitzal F; Hochreiner G; Wette V; Sevelda P; Ploner F; Bartsch R; Fesl C; Greil R;
    Ann Oncol; 2015 Feb; 26(2):313-20. PubMed ID: 25403582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.